ModeX Advances Novel Tetraspecific Antibody Into First-in-Human Study for B‑Cell Lymphoma

As reported on PharmaBiz, ModeX Therapeutics, a clinical-stage biotechnology company within OPKO Health, has begun dosing patients in a first-in-human clinical trial evaluating MDX2003, a next-generation tetra-specific T‑cell engager for…

Continue Reading ModeX Advances Novel Tetraspecific Antibody Into First-in-Human Study for B‑Cell Lymphoma
ICYMI: LP-284 Earns Orphan Drug Designation for High-Grade B-Cell Lymphoma with MYC/BCL2 Rearrangements
PDPics / Pixabay

ICYMI: LP-284 Earns Orphan Drug Designation for High-Grade B-Cell Lymphoma with MYC/BCL2 Rearrangements

  Have you ever heard of Orphan Drug designation? This designation, granted by the U.S. Food and Drug Administration (FDA), is given to drugs or biologics that are designed to treat,…

Continue Reading ICYMI: LP-284 Earns Orphan Drug Designation for High-Grade B-Cell Lymphoma with MYC/BCL2 Rearrangements